Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 10, October, p. 1161–1167

doi: 10.17219/acem/125427

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Antiviral treatment in congenital HCMV infection: The six-year experience of a single neonatal center in Poland

Dominika Jedlińska-Pijanowska1,A,B,C,D,E,F, Justyna Czech-Kowalska1,A,B,C,D,E,F, Magdalena Kłodzińska1,B,C,D,E,F, Aleksandra Pietrzyk1,B,C,D,E,F, Eliza Michalska1,B,C,D,E,F, Kinga Gradowska1,B,C,D,E,F, Anna Dobrzańska1,A,B,C,E,F, Beata Kasztelewicz2,B,C,D,E,F, Dariusz Gruszfeld1,A,B,C,E,F

1 Neonatal Intensive Care Unit, The Children’s Memorial Health Institute, Warsaw, Poland

2 Department of Clinical Microbiology and Immunology, The Children’s Memorial Health Institute, Warsaw, Poland

Abstract

Background. Antiviral treatment is recommended for symptomatic newborns with congenital cytomegalovirus infection (cCMV).
Objectives. To compare 2 treatment methods in neonates with cCMV – ganciclovir-based therapy (intravenous ganciclovir (GCV) or sequential GCV + valganciclovir (VGCV) therapy) with oral VGCV-based therapy – in Polish neonates.
Material and Methods. A total of 98 symptomatic infants with cCMV (positive HCMV DNA in urine ≤21st day of life) hospitalized in the neonatal intensive care unit (NICU) between 2012 and 2017 were enrolled. Clinical characteristics, the viral load in blood and urine, hematological and biochemical tests, neuroimaging results, and the length of hospitalization were compared between the study groups at baseline and at the 2nd hospitalization.
Results. In 2012, GCV was used in 57% of the cases, sequential therapy in 33% and VGCV in 10%. In 2017, VGCV monotherapy was used in 83% of the infants treated. Valganciclovir treatment allowed the length of hospitalization to be shortened over 2.5 times during the six-year observation period. Infants treated intravenously had lower birth weights and head circumferences, and more frequently presented splenomegaly, petechiae, thrombocytopenia, and hepatitis. The baseline viral load in the blood and urine were similar in both groups, but at follow-up visits 4–6 weeks later, a viral load about 70 times lower was observed in the blood of the VGCV-based group (1029 viral copies/mL compared to 72,188 viral copies/mL in the GCV-based group; p = 0.04). The prevalence of neutropenia was similar in both groups at the follow-up visits.
Conclusion. Valganciclovir became the first line of antiviral therapy in cCMV in the study population. Compared to GCV-based therapy, VGCV monotherapy allowed shorter hospital stays and reduced the viral load in blood due to continuing treatment at home. Valganciclovir monotherapy did not provoke more side effects such as neutropenia. Intravenous GCV is still suitable for patients with severe disseminated disease, born prematurely, with low birth weights, or not tolerating enteral feeding. In those infants, the sequential therapy seems to be optimal.

Key words

congenital, human cytomegalovirus, ganciclovir, valganciclovir, cytomegaly

References (27)

  1. Gelemanovic A, Dobberpuhl K, Krakar G, Patarčić I, Kolčić I, Polašek O. Host genetics and susceptibility to congenital and childhood cytomegalovirus infection: A systematic review. Croat Med J. 2016;57(4):321–330.
  2. Marsico C, Kimberlin DW. Congenital cytomegalovirus infection: Advances and challenges in diagnosis, prevention and treatment. Ital J Pediatr. 2017;43(1):38.
  3. Khalil A, Heath P, Jones C, Soe A, Ville YG; on behalf of the Royal College of Obstetricians and Gynaecologists. Congenital cytomegalovirus infection: Update on treatment. BJOG. 2018;56:e1–e11.
  4. Plosa EJ, Esbenshade JC, Fuller MP, Weitkamp JH. Cytomegalovirus infection. Pediatr Rev. 2012;33(4):156–163.
  5. Leung J, Dollard SC, Grosse SD, et al. Valganciclovir use among commercially and Medicaid-insured infants with congenital CMV infection in the United States, 2009–2015. Clin Ther. 2018;40(3):430–439.e431.
  6. Bartlett AW, Hall BM, Palasanthiran P, McMullan B, Shand AW, Rawlinson WD. Recognition, treatment, and sequelae of congenital cytomegalovirus in Australia: An observational study. J Clin Virol. 2018;108:121–125.
  7. Dietrich ML, Schieffelin JS. Congenital cytomegalovirus infection. Ochsner J. 2019;19(2):123–130.
  8. Zhang XY, Fang F. Congenital human cytomegalovirus infection and neurologic diseases in newborns. Chin Med J (Engl). 2019;132(17):2109–2118.
  9. Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: Consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017;17(6):e177–e188.
  10. Luck SE, Wieringa JW, Blazquez-Gamero D, et al; ESPID Congenital CMV Group Meeting, Leipzig 2015. Congenital cytomegalovirus: A European Expert Consensus Statement on Diagnosis and Management. Pediatr Infect Dis J. 2017;36(12):1205–1213.
  11. Kimberlin DW, Jester PM, Sanchez PJ, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372(10):933–943.
  12. Kimberlin DW, Lin CY, Sanchez PJ, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. J Pediatr. 2003;143(1):16–25.
  13. Kimberlin DW, Acosta EP, Sanchez PJ, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008;197(6):836–845.
  14. Kimberlin DB, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:317–322.
  15. Kasztelewicz B, Czech-Kowalska J, Lipka B, et al. Cytokine gene polymorphism associations with congenital cytomegalovirus infection and sensorineural hearing loss. Eur J Clin Microbiol Infect Dis. 2017;36(10):1811–1818.
  16. Kadambari S, Williams EJ, Luck S, Griffiths PD, Sharland M. Evidence-based management guidelines for the detection and treatment of congenital CMV. Early Hum Dev. 2011;87(11):723–728.
  17. Niezgoda A, Czech-Kowalska J, Piłat K, et al. Congenital CMV infection: Guidelines. Stand Med Ped. 2018;2:172–177.
  18. Lisowska-Mikołajków D. Mikołajków A, Reczuch J. Królak-Olejnik B. Congenital cytomegalovirus infection: Still a relevant problem (based on own experience and literature) [in Polish]. Dev Period Med. 2018;22(1):49–57.
  19. Amir J, Wolf DG, Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr. 2010;169(9):1061–1067.
  20. Marsico C, Aban I, Kuo H, et al; Collaborative Antiviral Study Group (CASG). Blood viral load in symptomatic congenital cytomegalo­virus infection. J Infect Dis. 2019;219(9):1398–1406.
  21. Boppana SB, Fowler KB, Pass RF, et al. Congenital cytomegalovirus infection: Association between virus burden in infancy and hearing loss. J Pediatr. 2005;146(6):817–823.
  22. Whitley RJ, Cloud G, Gruber W, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: Results of a phase II study. J Infect Dis. 1997;175(5):1080–1086.
  23. Tanaka-Kitajima N, Sugaya N, Futatani T, et al. Ganciclovir therapy for congenital cytomegalovirus infection in six infants. Pediatr Infect Dis J. 2005;24(9):782–785.
  24. Ronchi A, Pietrasanta C, Binda S, Mosca F, Pugni L. Congenital cytomegalovirus infection and antiviral therapy: How to manage neutropenia properly? Pediatr Infect Dis J. 2019;38(8):e190.
  25. Ziv L, Yacobovich J, Pardo J, et al. Hematologic adverse events associated with prolonged valganciclovir treatment in congenital cytomegalovirus infection. Pediatr Infect Dis J. 2019;38(2):127–130
  26. Ohyama S, Fujioka K, Fukushima S, et al. Diagnostic value of cytomegalovirus IgM antibodies at birth in PCR-confirmed congenital cytomegalovirus infection. Int J Mol Sci. 2019;20(13):3239.
  27. Fukushima S, Morioka I, Ohyama S, et al. Prediction of poor neurological development in patients with symptomatic congenital cytomegalovirus diseases after oral valganciclovir treatment. Brain Dev. 2019;41(9):743–750.
© Wroclaw Medical University